{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036820","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.177281+00:00","generated_at":"2026-05-24T23:44:14.266871+00:00","sec_items":["1.01","2.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Viking signs $150M manufacturing deal with CordenPharma for VK2735 supply","bullets":["Viking prepays $150M over 2025-2028 for dedicated API and fill/finish capacity for obesity drug VK2735.","CordenPharma commits to multi-ton annual API supply; dedicated lines for 100M autoinjectors and 100M vial/syringe units.","Annual oral tablet capacity exceeds 1 billion units; capacities are expandable at Viking's option.","Phase 3 subcutaneous VK2735 trial planned to start Q2 2025; oral Phase 2 VENTURE trial ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036820","json":"https://secwatch.observer/filing/0000950170-25-036820.json","markdown":"https://secwatch.observer/filing/0000950170-25-036820.md","text":"https://secwatch.observer/filing/0000950170-25-036820.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025036820/0000950170-25-036820-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017025036820/vktx-20250310.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T23:44:14.266871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}